162 related articles for article (PubMed ID: 16192318)
1. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.
McStay MK; Maudgil D; Williams M; Tibballs JM; Watkinson AF; Caplin ME; Buscombe JR
Radiology; 2005 Nov; 237(2):718-26. PubMed ID: 16192318
[TBL] [Abstract][Full Text] [Related]
2. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
3. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma.
Leimer M; Kurtaran A; Smith-Jones P; Raderer M; Havlik E; Angelberger P; Vorbeck F; Niederle B; Herold C; Virgolini I
J Nucl Med; 1998 Dec; 39(12):2090-4. PubMed ID: 9867148
[TBL] [Abstract][Full Text] [Related]
4. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
Virgolini I; Britton K; Buscombe J; Moncayo R; Paganelli G; Riva P
Semin Nucl Med; 2002 Apr; 32(2):148-55. PubMed ID: 11965610
[TBL] [Abstract][Full Text] [Related]
5. Intraarterial Peptide Receptor Radionuclide Therapy Using
Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
[TBL] [Abstract][Full Text] [Related]
6. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
[TBL] [Abstract][Full Text] [Related]
7. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
Sato KT; Lewandowski RJ; Mulcahy MF; Atassi B; Ryu RK; Gates VL; Nemcek AA; Barakat O; Benson A; Mandal R; Talamonti M; Wong CY; Miller FH; Newman SB; Shaw JM; Thurston KG; Omary RA; Salem R
Radiology; 2008 May; 247(2):507-15. PubMed ID: 18349311
[TBL] [Abstract][Full Text] [Related]
8. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
[TBL] [Abstract][Full Text] [Related]
9. Changes in the expression of somatostatin receptor imaging following Y-90 lanreotide therapy for carcinoid tumor: a flare response?
Popadic S; Al-Nahhas A; Naili Q; Todd J; Meeran K
Clin Nucl Med; 2005 Apr; 30(4):238-40. PubMed ID: 15764878
[TBL] [Abstract][Full Text] [Related]
10. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
[TBL] [Abstract][Full Text] [Related]
11. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study.
Kalinowski M; Dressler M; König A; El-Sheik M; Rinke A; Höffken H; Gress TM; Arnold R; Klose KJ; Wagner HJ
Digestion; 2009; 79(3):137-42. PubMed ID: 19307736
[TBL] [Abstract][Full Text] [Related]
12. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
Imhof A; Brunner P; Marincek N; Briel M; Schindler C; Rasch H; Mäcke HR; Rochlitz C; Müller-Brand J; Walter MA
J Clin Oncol; 2011 Jun; 29(17):2416-23. PubMed ID: 21555692
[TBL] [Abstract][Full Text] [Related]
13. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
14. "MAURITIUS": tumour dose in patients with advanced carcinoma.
Virgolini I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Smith-Jones P
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S227-30. PubMed ID: 10604137
[TBL] [Abstract][Full Text] [Related]
15. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
Diamandidou E; Ajani JA; Yang DJ; Chuang VP; Brown CA; Carrasco HC; Lawrence DD; Wallace S
AJR Am J Roentgenol; 1998 Feb; 170(2):339-44. PubMed ID: 9456942
[TBL] [Abstract][Full Text] [Related]
16. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
[TBL] [Abstract][Full Text] [Related]
17. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.
Filippi L; Scopinaro F; Pelle G; Cianni R; Salvatori R; Schillaci O; Bagni O
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):432-40. PubMed ID: 26323577
[TBL] [Abstract][Full Text] [Related]
18. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.
Virgolini I; Traub T; Leimer M; Novotny C; Pangerl T; Ofluoglu S; Halvadjieva E; Smith-Jones P; Flores J; Li SR; Angelberger P; Havlik E; Andreae F; Raderer M; Kurtaran A; Niederle B; Dudczak R
Q J Nucl Med; 2000 Mar; 44(1):50-8. PubMed ID: 10932601
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.
Buscombe JR; Caplin ME; Hilson AJ
J Nucl Med; 2003 Jan; 44(1):1-6. PubMed ID: 12515868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
